20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326
Completed
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
11/13/2023
Locations: The Vancouver Clinic, Inc, Vancouver, Washington
Conditions: Pneumococcal Disease
Register for Updates
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
NCT00513526
Completed
RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine therapy works in treating men with HIV-1 infection.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/27/2023
Locations: Benaroya Research Institute at Virginia Mason Medical Center, Seattle, Washington
Conditions: Infection, Precancerous Condition
Register for Updates
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
NCT05047770
Completed
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, when administered sequentially or co-administered with Moderna's mRNA-1273 booster vaccination against COVID-19.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: GSK Investigational Site, Cheney, Washington +1 locations
Conditions: Herpes Zoster
Register for Updates
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
NCT04952402
Completed
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: • People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study. And • People who have never had COVID-19 (SARS-CoV-2 infection).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2023
Locations: University of Washington AIDS CRS, Seattle, Washington
Conditions: Covid19, SARS-CoV2 Infection
Register for Updates
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
NCT03620162
Completed
The goal of this study is to evaluate the safety, tolerability, and immunogenicity of the Pneumococcal Conjugate Vaccines (PCVs) V114 and Prevnar 13™ in healthy infants switched from Prevnar 13™ to V114 during the four-dose PCV immunization schedule.
Gender:
ALL
Ages:
Between 42 days and 90 days
Trial Updated:
01/12/2023
Locations: Multicare ( Site 0019), Spokane, Washington
Conditions: Pneumococcal Infections
Register for Updates
Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
NCT02852005
Completed
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the AIDSVAX B/E vaccine and the MVA/HIV62B vaccine in healthy, HIV-1-uninfected adults who previously received MVA/HIV62B in DNA/MVA or MVA/MVA vaccine regimens in the HVTN 205 study.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/04/2022
Locations: Seattle Vaccine and Prevention CRS, Seattle, Washington
Conditions: HIV Infections
Register for Updates
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
NCT00820846
Completed
The purpose of this study is to evaluate the safety of and immune response to a two-vaccine regimen in healthy, HIV-uninfected adults who have never received an HIV preventive vaccine before.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/04/2022
Locations: Seattle Vaccine and Prevention CRS, Seattle, Washington
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
NCT03934541
Completed
The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/15/2022
Locations: Seattle Vaccine and Prevention CRS, Seattle, Washington
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
NCT02915016
Completed
This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/27/2022
Locations: Seattle Vaccine and Prevention CRS, Seattle, Washington
Conditions: HIV Infections
Register for Updates
HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study
NCT03560258
Completed
This study evaluated the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons who were on antiretroviral therapy (ART). The study aimed to induce potent virus-specific cytotoxic T lymphocytes (CTL) responses.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/28/2022
Locations: University of Washington AIDS CRS, Seattle, Washington
Conditions: HIV Infections
Register for Updates
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
NCT02199691
Completed
The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed vaccine MENVEO® in adolescents 10 to 17 years of age in the United States (US). This study also evaluated the immunogenicity and safety of MenACYW Conjugate vaccine when given alone compared to when given concomitantly with tetanus, diphtheria, acellular pertussis (Tdap) vaccine and human... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
03/24/2022
Locations: Not set, Spokane, Washington +1 locations
Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Register for Updates
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
NCT01049035
Completed
The purpose of this study was to evaluate the optimal vaccination schedule for a Quadrivalent Meningococcal Polysaccharide (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (MenACYW Conjugate vaccine) in order to provide an effective protein conjugate quadrivalent meningococcal vaccine in the population with the highest incidence of disease. Objectives: * To describe the safety profile of MenACYW Conjugate vaccine administered at 5 different schedules and concomitantly with routine pediatr... Read More
Gender:
ALL
Ages:
Between 42 days and 365 days
Trial Updated:
03/21/2022
Locations: Not set, Spokane, Washington +1 locations
Conditions: Meningitis, Meningococcal Infection
Register for Updates